Inhibitors of phospholipase A₂ and their therapeutic potential: an update on patents (2012-2016)

References

• Dennis EA, Cao J, Hsu YH, et al. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev. 2011;111:6130–6185.
   PubMed Web of Science ®Google Scholar
• Dennis EA, Norris PC. Eicosanoid storm in infection and inflammation. Nat Rev Immunol. 2015;15:511–523.
   PubMed Web of Science ®Google Scholar
• Barbayianni E, Kaffe E, Aidinis V, et al. Autotaxin, a secreted lysophospholipase D, as a promising therapeutic target in chronic inflammation and cancer. Prog Lipid Res. 2015;58:76–96.
   PubMed Web of Science ®Google Scholar
• Magrioti V, Kokotos G. Phospholipase A2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases. Expert Opin Ther Pat. 2010;23:333–344.
   Web of Science ®Google Scholar
• Magrioti V, Kokotos G. Phospholipase A2 inhibitors for the treatment of inflammatory diseases: a patent review (2010 – present). Expert Opin Ther Pat. 2013;20:1–18.
   Web of Science ®Google Scholar
• Samanta U, Bahnson B. J. Crystal structure of human plasma platelet-activating factor acetylhydrolase: structural implication to lipoprotein binding and catalysis. J Biol Chem. 2008;283:31617–31624.
   PubMed Web of Science ®Google Scholar
• Samanta U, Kirby SD, Srinivasan P, et al. Crystal structures of human group-VIIA phospholipase A2 inhibited by organophosphorus nerve agents exhibit non-aged complexes. Biochem Pharmacol. 2009;78:420–429.
   PubMed Web of Science ®Google Scholar
• Liu Q, Chen X, Chen W, et al. Structural and thermodynamic characterization of protein−ligand interactions formed between lipoprotein-associated phospholipase A2 and inhibitors. J Med Chem. 2016;59:5115–5120.
   PubMed Web of Science ®Google Scholar
• Chen X, Wang K, Xu W, et al. Discovery of potent and orally active lipoprotein associated phospholipase A2 (Lp-PLA2) inhibitors as a potential therapy for diabetic macular edema. J Med Chem. 2016;59:2674–2687.
   PubMed Web of Science ®Google Scholar
• Mouchlis VD, Bucher D, McCammon JA, et al. Membranes serve as allosteric activators of phospholipase A2, enabling it to extract, bind, and hydrolyze phospholipid substrates. PNAS. 2015;112:E516eE525.
   Web of Science ®Google Scholar
• Mouchlis VD, Dennis EA. Membrane and inhibitor interactions of intracellular phospholipases A2. Adv Biol Regul. 2016;61:17–24.
   PubMedGoogle Scholar
• Mouchlis VD, Limnios D, Kokotou MG, et al. Development of potent and selective inhibitors for group VIA calcium-independent phospholipase A2 guided by molecular dynamics and structure-activity relationships. J Med Chem. 2016;59:4403–4441.
   PubMed Web of Science ®Google Scholar
• Vasilakaki S, Barbayianni E, Leonis G, et al. Development of a potent 2-oxoamide inhibitor of secreted phospholipase A2 guided by molecular docking calculations and molecular dynamics simulations. Bioorg Med Chem. 2016;24:1683–1695.
   PubMed Web of Science ®Google Scholar
• Tellis CC, Tselepis AD. Pathophysiological role and clinical significance of lipoprotein-associated phospholipase A2 (Lp-PLA2) bound to LDL and HDL. Curr Pharm Des. 2014;20:6256–6269.
   PubMed Web of Science ®Google Scholar
• Arensdorf PA, Cerelli MJ, Gerwien RW Jr, et al. Methods for treatment of coronary heart disease events based of lipoprotein-associated phospholipase A₂ activity. US2015353986. 2015.
   Google Scholar
• Blackie JA, Bloomer JC, Brown MJB, et al. The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2. Bioorg Med Chem Lett. 2003;13:1067–1070.
   PubMed Web of Science ®Google Scholar
• White HD, Held C, Stewart R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Eng J Med. 2014;370:1702–1711.
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Braunwald E, White HD, et al. Effect of darapladib on major coronary events after an acute coronary syndrome. JAMA. 2014;312:1006–1015.
   PubMed Web of Science ®Google Scholar
• Auspex Pharmaceutics Inc. Pyrimidinone inhibitors of lipoprotein-associated phospholipase A₂. US2014/0107135. 2014.
   Google Scholar
• Auspex Pharmaceuticals Inc. Quinolone inhibitors of lipoprotein-associated phospholipase A₂. US2015/0094331. 2015.
   Google Scholar
• GlaxoSmithKline. 2-3-Dihydroimidazol[1,2-C]pyrimidin-5(1H)-one based lipoprotein-associated phospholipase A₂ (LP-PLA₂) inhibitors. WO2014114694. 2014.
   Google Scholar
• Perampalli Nekkar PR, Nambil Kabir S Indolizine derivatives. US2015/0025105. 2015.
   Google Scholar
• Chen X, Xu W, Wang K, et al. Discovery of a novel series of imidazo[1,2-a]pyrimidine derivatives as potent and orally bioavailable lipoprotein-associated phospholipase A2 inhibitors. J Med Chem. 2015;58:8529–8541.
   PubMed Web of Science ®Google Scholar
• Woolford -AJ-A, Pero JE, Aravapalli S, et al. Exploitation of a novel binding pocket in human lipoprotein-associated phospholipase A2 (Lp-PLA2) discovered through X-ray fragment screening. J Med Chem. 2016;59:5356–5367.
   PubMed Web of Science ®Google Scholar
• Leslie CC. Cytosolic phospholipase A2: physiological function and role in disease. J Lipid Res. 2015;56:1386–1402.
   PubMed Web of Science ®Google Scholar
• Lee KL, Foley MA, Chen L, et al. Discovery of ecopladib, an indole inhibitor of cytosolic phospholipase A2α. J Med Chem. 2007;50:1380–1400.
   PubMed Web of Science ®Google Scholar
• McKew JC, Lee KL, Shen MWH, et al. Indole cytosolic phospholipase A2α inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib. J Med Chem. 2008;51:3388–3413.
   PubMed Web of Science ®Google Scholar
• http://clinicaltrials.gov/Identifier: NCT00396955
   Google Scholar
• Hewson CA, Patel S, Calzetta L, et al. Preclinical evaluation of an inhibitor of cytosolic phospholipase A2a for the treatment of asthma. J Pharmacol Exp Ther. 2012;340:656–665.
   PubMed Web of Science ®Google Scholar
• Avexxin AS Antiinflammatory 2-oxothiazoles and 2-oxooxazoles. WO2011039365. 2011.
   Google Scholar
• Kokotos G, Feuerherm AJ, Barbayianni E, et al. Inhibition of group IVA cytosolic phospholipase A2 by thiazolyl ketones in vitro, ex vivo, and in vivo. J Med Chem. 2014;57:7523–7535.
   PubMed Web of Science ®Google Scholar
• Avexxin AS Antinflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds. WO2014118195. 2014.
   Google Scholar
• Avexxin AS 2-Oxothiazole compounds having activity as cPLA₂ inhibitors for the treatment of inflammatory disorders and hyperproliferative disorders. WO2016016472. 2016.
   Google Scholar
• Eugene K, Hanna MT, Jana C, et al. Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model. BMC Cancer. 2016;16:191.
   PubMed Web of Science ®Google Scholar
• Tomoo T, Nakatsuka T, Katayama T, et al. Design, synthesis, and biological evaluation of 3-(1-aryl-1H-indol-5-yl)propanoic acids as new indole-based cytosolic phospholipase A2α inhibitors. J Med Chem. 2014;57:7244–7262.
   PubMed Web of Science ®Google Scholar
• Terakawa M, Goto M, Tomoo T, et al. cPLA2α inhibitor ASB14780 suppresses airway MMP-9 production and improves respiratory function in cigarette-smoke induced model. Eur Respir J. 2014;44:P1790.
   Google Scholar
• Kanai S, Ishihara K, Kawashita E, et al. ASB14780, an orally active inhibitor of group IVA phospholipase A2, is a pharmacotherapeutic candidate for non-alcoholic fatty liver disease. J Pharmacol Exp Ther. 2016;1521:604–614.
   Web of Science ®Google Scholar
• Murakami M, Sato H, Miki Y. A new era of secreted phospholipase A2. J Lipid Res. 2015;56:1248–1261.
   PubMed Web of Science ®Google Scholar
• Draheim SE, Bach NJ, Dillard RD, et al. Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides. J Med Chem. 1996;39:5159–5175.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Kastelein JJP, Schwartz GG, et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome. JAMA. 2014;311:252–262.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Miki Y, Sato M, et al. The role of group IIF-secreted phospholipase A2 in epidermal homeostasis and hyperplasia. J Exp Med. 2015;212:1901–1919.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Miki Y, Sato M, et al. Expression and function of group IIE phospholipase A2 in mouse skin. J Biol Chem. 2016. DOI:10.1074/jbc.M116.734657
   Web of Science ®Google Scholar
• Murase R, Sato H, Yamamoto K, et al. Group X secreted phospholipase A2 releases ω3 polyunsaturated fatty acids, suppresses colitis, and promotes sperm fertility. J Biol Chem. 2016;291:6895–6911.
   PubMed Web of Science ®Google Scholar
• Nahed RA, Martinez G, Escoffier J, et al. Progesterone-induced acrosome exocytosis requires sequential involvement of calcium-independent phospholipase A2β (iPLA2β) and group X secreted phospholipase A2 (sPLA2). J Biol Chem. 2016;291:3076–3089.
   PubMed Web of Science ®Google Scholar
• Brglez V, Lambeau G, Petan T. Secreted phospholipases A2 in cancer: diverse mechanisms of action. Biochimie. 2014;107:114–123.
   PubMed Web of Science ®Google Scholar
• Miki Y, Kidoguchi Y, Sato M, et al. Dual roles of group IID phospholipase A2 in inflammation and cancer. J Biol Chem. 2016. DOI:10.1074/jbc.M116.734624
   Web of Science ®Google Scholar
• Ramanadham S, Ali T, Ashley JW. Calcium-independent phospholipases A2 and their roles in biological processes and diseases. J Lipid Res. 2015;56:1643–1668.
   PubMed Web of Science ®Google Scholar
• Ong W-Y, Farooqui T, Kokotos G, et al. Synthetic and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders. ACS Chem Neurosci. 2015;6:814–831.
   PubMed Web of Science ®Google Scholar
• Kokotos G, Hsu Y-H, Burke JE, et al. Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2. J Med Chem. 2010;53:3602–3610.
   PubMed Web of Science ®Google Scholar
• Ali T, Kokotos G, Magrioti V, et al. Characterization of FKGK18 as inhibitor of group VIA Ca2+-independent phospholipase A2 (iPLA2β): candidate drug for preventing beta-cell apoptosis and diabetes. Plos One. 2013;8:e71748.
   PubMed Web of Science ®Google Scholar
• Bone RN, Gai Y, Magrioti V, et al. Inhibition of Ca2+-independent phospholipase A2β (iPLA2β) ameliorates islet infiltration and incidence of diabetes in NOD mice. Diabetes. 2015;64:541–554.
   PubMed Web of Science ®Google Scholar
• Lee DM, Boilard E, Gelb MH, G R. Secreted phospholipase A₂ biomarkers for arthritis. US2012/0122117. 2012.
   Google Scholar
• University of Cincinnati. Serum sPLA₂-IIA as diagnosis marker for prostate and lung cancer. US2012/0276552. 2012.
   Google Scholar
• Deregnaucourt C, Lambeau G, Guillaume C, et al. Use of secreted phospholipases A₂ in the diagnosis and treatment of malaria. US2012/0282238. 2012
   Google Scholar
• University of Cincinnati. Serum sPLA₂-IIA as diagnosis marker for prostate and lung cancer. US2013/0095503. 2013.
   Google Scholar
• Philadelphia Health and Education Corporation. Methods for monitoring neuroinflammatory destruction of neurons and for treating diseases having an inflammatory component related to phospholipase A₂. US2015/0079607. 2015.
   Google Scholar
• Montaner J, Delgado Martinez MP Methods using lipoprotein-associated phospholipase A₂ in an acute care setting. US2013/0236450. 2013.
   Google Scholar
• Diadexus INC. Long shelf-life kits and methods for standardizing, verifying, calibrating or recalibrating detection of lipoprotein-associated phospholipase A₂. WO2015/048177. 2015.
   Google Scholar
• Miller PL, Corral L Lipoprotein-associated phospholipase A₂ antibody compositions and methods of use. US2015/0203590. 2015.
   Google Scholar
• Lambeau G, Ancian P, Barhanin J, et al. Cloning and expression of a membrane receptor for secretory phospholipases A2. J Biol Chem. 1994;269:1575–1578.
   PubMed Web of Science ®Google Scholar
• Beck LH, Bonegio RGB, Lambeau G, et al. M-Type phospholipase A2 receptor as target aqntigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361:11–21.
   PubMed Web of Science ®Google Scholar
• Seitz-Polski B, Dolla G, Payré C, et al. Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy. J Am Soc Nephrol. 2016;27:1517–1533.
   PubMed Web of Science ®Google Scholar
• Murakami M, Taketomi Y, Yoshimi M, et al. Emerging roles of secreted phospholipase A2 enzymes: the 3rd edition. Biochimie. 2014;107:105e113.
   Web of Science ®Google Scholar
• Girard CA, Seitz-Polski B, Dolla G, et al. Nouveaux rôles physiopathologiques pour le récepteur PLA2R1 dans le cancer et la glomérulonéphrite extramembraneuse. Medecine/Sciences. 2014;30:519–525.
   Google Scholar
• Fujita M, Zhu K, Fujita CK, et al. Proinflammatory secreted phospholipase A2 type IIA (sPLA-IIA) induces integrin activation through direct binding to a newly identified binding site (Site 2) in integrins αvβ3, α4β1, and α5β1. J Biol Chem. 2015;290:259–271.
   PubMed Web of Science ®Google Scholar
• Ye L, Dickerson T, Kaur H, et al. Identification of inhibitors against interaction between pro-inflammatory sPLA2-IIA protein and integrin avb3. Bioorg Med Chem Lett. 2013;23:340–345.
   PubMed Web of Science ®Google Scholar
• Jiansgsu Institute of Nuclear Medicine. Test strip for detecting M type phospholipase A₂ receptor auto-antibodies and detection card thereof. CN204374215. 2014.
   Google Scholar
• Jiansgsu Institute of Nuclear Medicine. M-type phospholipase A₂ receptor autoantibody detection reagent box. CN204188620. 2014.
   Google Scholar
• Shenzen Blot Biotech Co. PLA₂R (phospholipase A₂ receptor) antibody detection strip and preparation method and detection method thereof. CN104880560. 2015.
   Google Scholar
• National University Corporation Nagoya University. Simplified measurement of anti-phospholipase A₂ receptor antibody. WO2016/009971. 2016.
   Google Scholar
• Hsu Y-H, Bucher D, Cao J, et al. Fluoroketone inhibition of Ca2+-independent phospholipase A2 through binding pocket association defined by hydrogen/deuterium exchange and molecular dynamics. J Am Chem Soc. 2013;135:1330–1337.
   PubMed Web of Science ®Google Scholar
• Talmud PJ, Holmes MV. Deciphering the causal role of sPLA2s and Lp-PLA2 in coronary heart disease. Arterioscler Thromb Vasc Biol. 2015;35:2281–2289.
   PubMed Web of Science ®Google Scholar
• Ueshima H, Kadowaki T, Hisamatsu T, et al. Lipoprotein-associated phospholipase A2 is related to risk of subclinical atherosclerosis but is not supported by Mendelian randomization analysis in a general Japanese population. Atherosclerosis. 2016;246:141–147.
   PubMed Web of Science ®Google Scholar
• Jensen MK, Bertoia ML, Cahill LE, et al. Novel metabolic biomarkers of cardiovascular disease. Nat Rev Endocrinol. 2014;10:659–672.
   PubMed Web of Science ®Google Scholar
• Hassan M. STABILITY and SOLID-TIMI 52: lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases. Glob Cardiol Sci Pract. 2015;6. DOI:10.5339/gcsp.2015.6
   PubMedGoogle Scholar
• Vasilakaki S, Barbayianni E, Magrioti V, et al. Inhibitors of secreted phospholipase A2 suppress the release of PGE2 in renal mesangial cells. Bioorg Med Chem. 2016;24:3029–3034.
   PubMed Web of Science ®Google Scholar